New guidelines for treating methicillin-resistant S. aureus (MRSA) will change treatment of community-acquired skin infections

February 2011

New guidelines for treating methicillin-resistant S. aureus (MRSA) will change treatment of community-acquired skin infections.

A beta-lactam (cephalexin, etc) USED to cover both purulent skin infections due to staph and cellulitis due to strep.

But now most staph skin infections are due to community-acquired methicillin-resistant Staph aureus (CA-MRSA) and therefore are resistant to beta-lactams.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: PA includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote